AN2 Therapeutics, Inc.
ANTX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.02 | 0.03 | 0.06 |
| FCF Yield | -23.76% | -25.99% | -12.79% | -37.60% |
| EV / EBITDA | -1.91 | -1.81 | -2.64 | 0.13 |
| Quality | ||||
| ROIC | -9.79% | -15.73% | -10.50% | -15.98% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.68 | 1.18 | 1.00 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 28.47% | -101.48% | 56.08% | 16.53% |
| Safety | ||||
| Net Debt / EBITDA | 2.52 | 1.73 | 2.84 | 2.85 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |